Ausgabe 3/1999
Inhalt (7 Artikel)
Transferrin receptor overexpression enhances transferrin responsiveness and the metastatic growth of a rat mammary adenocarcinoma cell line
Philip G. Cavanaugh, Li Bin Jia, Yi Yu Zou, Garth L. Nicolson
Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence–based amplification for the detection of circulating breast cancer cells
A.C. Lambrechts, A.J. Bosma, S.G. Klaver, B. Top, L. Perebolte, L.J. van't Veer, S. Rodenhuis
Weekly epirubicin plus lonidamine in advanced breast carcinoma
Cecilia Nisticò, Carlo Garufi, Michele Milella, Anna Maria D'Ottavio, Angela Vaccaro, Alessandra Fabi, Edmondo Terzoli
Cisplatin–epirubicin–paclitaxel weekly administration in advanced breast cancer: A phase I study of the Southern Italy Cooperative Oncology Group
Giuseppe Frasci, Giuseppe D'Aiuto, Pasquale Comella, Anna Apicella, Renato Thomas, Immacolata Capasso, Maurizio Di Bonito, Giacomo Cartenì, Maria Biglietto, Luigi De Lucia, Luigii Maiorino, Sergio Piccolo, Ugo Bianchi, Roberta D'Aniello, Liliana Lapenta, Giuseppe Comella
pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers
Bradley E. Gillesby, Timothy R. Zacharewski
Effective treatment of advanced estrogen–independent MXT mouse mammary cancers with targeted cytotoxic LH–RH analogs
Karoly Szepeshazi, Andrew V. Schally, Attila Nagy
Retinoic acid receptor antagonist BMS453 inhibits the growth of normal and malignant breast cells without activating RAR–dependent gene expression
L. Yang, D. Munoz–Medellin, H-T. Kim, J. Ostrowski, P. Reczek, P.H. Brown